Publication

[Cell Communication and Signaling] EMS affected ASC wells were treated with two different concentrations, 50 and 100 nM, of exogenous SHBG, whose biocompatibility was tested after 24, 48, and 72 h of incubation.

[Journal of Cellular and Molecular Medicine] Bioinformatics analysis was performed with non-small-cell lung cancer-related miRNA microarray GSE169587 and mRNA data GSE74706 obtained for collection of the differentially expressed miRNAs and mRNAs.

[Scientific Reports] Researchers exposed Saos-2 cells to different combinations of ascorbic acid (Asc), dexamethasone (Dex), and β-glycerophosphate (β-Gly) for 14 days and compared the response with immortalized human MSCs. Cell numbers, cytotoxicity, mineralized matrix deposition, and cell proliferation were analyzed to assess osteoblast-like behavior in the presence of Asc, Dex, and β-Gly.

[New England Journal Of Medicine] Scientists conducted an investigator-initiated, multicenter, single-group, Phase II study of the anti–programmed death ligand 1 agent atezolizumab in adult and pediatric patients with advanced alveolar soft part sarcoma.

[Clinical Cancer Research] The authors coordinated a first-in-kind Phase II clinical trial of the CDK4/6i abemaciclib for patients with progressive dedifferentiated liposarcoma with cellular studies interrogating the molecular basis of geroconversion.

[Cell Death Discovery] Investigators confirmed that fibronectin type III domain protein 5 (FNDC5) promoted the survival of transplanted bone marrow MSCs in a rat cerebral infarction model. Bioinformatic analysis and verification experiments revealed the transcription factor, Sp1, to be a key mediator of autophagy regulation by FNDC5.